Stockscreener 앱 받기
3.90
0.51%
-0.02
시간 외 거래:
3.86
-0.04
-1.03%
전일 마감가:
$3.92
열려 있는:
$3.94
하루 거래량:
5,009
Relative Volume:
1.09
시가총액:
$146.29M
수익:
$786.00K
순이익/손실:
$-72.06M
주가수익비율:
-2.0256
EPS:
-1.9254
순현금흐름:
$-59.83M
1주 성능:
+4.84%
1개월 성능:
+1.56%
6개월 성능:
-7.80%
1년 성능:
+3.72%
1일 변동 폭
$3.86
$4.00
1주일 범위
$3.71
$4.11
52주 변동 폭
$3.4101
$5.36
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Compare MOLN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.90 | 144.42M | 786.00K | -72.06M | -59.83M | -1.9254 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | H.C. Wainwright | Buy |
| 2022-08-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-12 | 재개 | SVB Leerink | Outperform |
모두보기
Molecular Partners Ag Adr 주식(MOLN)의 최신 뉴스
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - GlobeNewswire Inc.
Molecular Partners reports phase 1 data for cancer drug MP0317 By Investing.com - Investing.com Australia
Molecular Partners reports phase 1 data for cancer drug MP0317 - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April - MarketBeat
Head & ShouldersStock ScreenerCharts - Finviz
Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Molecular Partners stock rating at buy - Investing.com
H.C. Wainwright reiterates Molecular Partners stock rating at buy By Investing.com - Investing.com South Africa
Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%Still a Buy? - MarketBeat
Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9% - MarketBeat
HC Wainwright Brokers Increase Earnings Estimates for MOLN - Defense World
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential By Investing.com - Investing.com South Africa
TD Cowen reiterates Molecular Partners stock rating on radioligand platform potential - Investing.com
Molecular Partners' (MOLN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Molecular Partners (NASDAQ: MOLN) outlines DARPin pipeline and cash into 2028 - Stock Titan
Will Petrobras Pull Off Q4 Earnings Beat on Strong Production? - TradingView
Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday - Defense World
Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.5%Should You Sell? - MarketBeat
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready - Yahoo Finance
Research Analysts Offer Predictions for MOLN FY2025 Earnings - Defense World
Brokers Offer Predictions for MOLN FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings? - MarketBeat
Molecular Partners stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Molecular Partners stock initiated with Buy rating at H.C. Wainwright - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update - MarketBeat
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1% – Here’s What Happened - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1%Here's What Happened - MarketBeat
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners to cut workforce by a quarter - Reuters
Citius Oncology (CTOR) Short Interest & Short Float | Updated Apr 2026 $CTOR - MarketBeat
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com Nigeria
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com
Molecular Partners reports 2024 annual results - Investing.com
Molecular Partners (MOLN) Stock Forecast and Price Target 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (MIRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Stock Market News Today - Stock Titan
Stock Ratings and Recommendations: Understanding Analyst Ratings - MarketBeat
MAIA Biotechnology (MAIA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Acrivon Therapeutics (ACRV) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
MOLN LOSS ALERT: GLOBALLY RECOGNIZED ROSEN LAW FIRM - GlobeNewswire
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
US stock market gainers for the last week of April 2022 - Nairametrics
Molecular Partners ADRs Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Molecular Partners AG - GlobeNewswire
Annovis Bio (ANVS) Short Interest & Short Float | Updated Apr 2026 $ANVS - MarketBeat
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Molecular Partners Ag Adr (MOLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):